GlassScriptPhysician profile
Pamela A Sullivan
NPI 1033187828
$5,808.37
in general payments reported to CMS, 2019-2025
46 companies · $984 in 2025
The $984 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $465 · 2021: $939 · 2022: $848 · 2023: $817 · 2024: $1,044 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,795 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.73 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,035.37 | 2019-2024 | Ubrelvy, Qulipta, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $502.79 | 2021-2025 | |
| Evofem Biosciences, INC. | $400.78 | 2021-2025 | Phexxi, Solosec, Phexx |
| Novo Nordisk INC | $314.87 | 2019-2025 | Wegovy |
| Therapeuticsmd, INC. | $296.96 | 2019-2022 | |
| Sage Therapeutics, LLC | $270.07 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $242.28 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $230.74 | 2023-2025 | Veozah |
| Millicent US INC | $181.05 | 2024-2025 | Femlyv, Intrarosa |
| Bayer Healthcare Pharmaceuticals INC. | $163.07 | 2019-2025 | |
| Pfizer INC. | $160.18 | 2019-2025 | |
| Agile Therapeutics, INC. | $160.14 | 2021-2023 | Twirla |
| Hologic Sales and Service, LLC | $154.92 | 2021-2025 | Aptima, Thinprep 2000 Processor, Third Wave |
| Organon LLC | $142.67 | 2021-2025 | Nexplanon |
| Currax Pharmaceuticals LLC | $121.29 | 2020-2024 | Nexletol, Contrave |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $116.67 | 2021-2022 | |
| Shield Therapeutics INC | $103.85 | 2024-2025 | |
| Daiichi Sankyo INC. | $96.89 | 2019-2021 | |
| Amgen INC. | $82.56 | 2019-2025 | Prolia, Evenity |
| Lupin INC. | $81.44 | 2019-2021 | |
| Ethicon US, LLC | $71.73 | 2019-2021 | |
| Optumhealth Care Solutions, LLC | $70.29 | 2024-2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Avion Pharmaceuticals | $66.85 | 2021-2023 | Balcoltra |
| Mission Pharmacal Company | $63.55 | 2019-2020 | |
| Myriad Women'S Health, INC. | $52.44 | 2023 | Myrisk |
| Exeltis, USA INC. | $49.92 | 2022-2025 | Slynd |
| Mylan Pharmaceuticals INC. | $48.87 | 2021-2022 | |
| Kvk-Tech, INC. | $47.83 | 2025 | |
| Vertical Pharmaceuticals, LLC | $45.22 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.20 | 2019-2022 | |
| Covidien LP | $40.70 | 2019 | |
| Amag Pharmaceuticals, INC. | $39.61 | 2019 | |
| Lilly USA, LLC | $38.89 | 2020-2025 | Zepbound, Mounjaro |
| Aspira Women'S Health INC | $32.71 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $29.15 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.56 | 2025 | Qelbree |
| Zyla Life Sciences, INC. | $25.15 | 2020 | |
| Lsi Solutions INC | $24.66 | 2023 | Running Device |
| Davol INC. | $24.64 | 2022 | |
| Exact Sciences Corporation | $23.48 | 2025 | Cologuard Collection Kit |
| Coopersurgical, INC. | $16.09 | 2019 | |
| Scynexis, INC. | $14.67 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.48 | 2022 | |
| Boston Scientific Corporation | $14.38 | 2025 | Bulkamid |
| Medtronic, INC. | $12.88 | 2022 | |
| Duchesnay USA Incorporated | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.